Medpace Holdings, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Financial statements are unaudited; comparisons are with Q1 2020 unless noted. Medpace is a global clinical research organization providing Phase I–IV development services to pharmaceutical, biotechnology, and medical-device companies.
Financial performance and liquidity
- Revenue: $260.0 million, up 12.6% from $230.9 million. Growth was led by Oncology, AVAI, and other therapeutic areas.
- Profitability: Operating income was $47.6 million, up 34.1%; operating margin was 18.3%, versus 15.4%. Net income was $43.3 million, up 49.6%; net margin was 16.7%, versus 12.5%. Diluted EPS was $1.14, versus $0.76.
- Costs: Total direct costs rose 9.5% to $181.5 million, slower than revenue growth. Management cited higher personnel costs and reimbursed out-of-pocket expenses. SG&A increased 2.4% to $25.7 million.
- Cash flow: Operating cash flow was $57.3 million, versus $49.1 million. Investing used $9.7 million, primarily for $6.5 million of property and equipment expenditures. Financing provided $9.1 million, mainly from stock-option exercises. Cash increased $55.1 million to $332.9 million.
- Liquidity and debt: Current assets were $533.4 million and current liabilities $447.3 million, a current ratio of approximately 1.19. The company reported no borrowings, with $49.8 million available under its $50 million credit facility; the facility was extended to March 31, 2022. Operating lease liabilities totaled $130.3 million.
- Other metrics: Backlog was $1.632 billion, up 26.1% from March 31, 2020. Net new business awards were $356.2 million, versus $246.9 million. The company estimated $850–$870 million of backlog would convert to revenue over the next 12 months. Remaining performance obligations for active projects were approximately $1.8 billion.
Material changes versus Q1 2020
- Revenue, operating income, net income, diluted EPS, and operating cash flow increased. Revenue growth exceeded growth in total direct costs and SG&A, supporting higher operating margin.
- The effective tax rate declined to 10.7% from 20.6%, primarily due to FDII benefits and excess tax benefits from share-based compensation.
- Cash was $332.9 million, compared with $134.0 million at March 31, 2020. Q1 2020 included $43.2 million of share repurchases; no repurchases were reported for Q1 2021. Remaining authorization at March 31, 2021 was $102.6 million.
Outlook, risks, and unusual items
- The filing provides no specific revenue or earnings guidance. Management expected COVID-19 effects to be temporary, but said the pandemic continued to disrupt operations and could continue to adversely affect results; the future financial impact could not be reasonably estimated.
- COVID-related site access restrictions, delayed patient enrollment and trial starts, study cancellations, and limited funding at smaller clients could affect service delivery and backlog conversion. Management noted use of alternative approaches, including virtual monitoring.
- Backlog and awards are not assured revenue measures: cancellations, scope changes, timing, and study duration can cause material fluctuations. Most customers can terminate contracts, typically with 30 days’ notice.
- Legal proceedings and recognized losses were described as immaterial; the company said potential additional losses were also believed to be immaterial. Project-supply purchase commitments totaled $12.6 million, expiring through 2027.
- Related-party transactions include clinical services, travel, and leases involving entities associated with the CEO and other company executives. The filing reports no material change in risk factors from the 2020 Form 10-K and no material change in market-risk disclosures.
Important facts for investors to verify
- Whether backlog growth converts to recognized revenue on the expected timeline, and how awards and cancellations develop.
- The extent and duration of COVID-related effects on clinical-site access, enrollment, study activity, and smaller clients’ funding.
- Whether the lower effective tax rate is sustainable, given the stated drivers of tax benefits.
- Cash deployment plans, including potential share repurchases, capital expenditures, and the substantial operating lease commitments.
- Terms, oversight, and financial effect of related-party service and real-estate arrangements.